ManagedCareHemo.com Presents Hemophilia Clinical Updates and Cost Management Solutions

• Release Date: September 30, 2019
• Expiration Date: March 31, 2021
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Shannon Carpenter, MD, MS Professor of Pediatrics, UMKC School of Medicine Hematology/Oncology, Director Kansas City Regional Hemophilia Treatment Center Director, Anticoagulation Management Program Children's Mercy Hospital Click here for biography Jeffrey Dunn, PharmD, MBA Vice President, Clinical Strategy and Programs and Industry Relations Magellan Rx Management  Click here for biography Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography

Target Audience

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, nurses, case managers, and social workers

Statement of Need/Program Overview 

The management of hemophilia is complex; however, appropriate management is vital to minimizing and/or preventing complications that can contribute to poorer health outcomes and higher health care resource utilization. Thus, there is a need for continued education in several key areas involving the effective management of patients with hemophilia in managed care and specialty pharmacy settings. The multidisciplinary faculty panel will emphasize the need for a well-coordinated patient management effort, the importance of understanding the most cost-effective ways of using available treatments, and the importance of collaboration among all stakeholders, which includes leveraging the success of the comprehensive care model utilized by HTCs.

Educational Objectives 
After completing this activity, the participant should be better able to: 

• Describe recent insights into the safety, efficacy, and attributes of recently approved and emerging hemophilia treatment options
• Review alignment of recently approved therapies in the current hemophilia treatment algorithm
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
• Apply processes for managed care and specialty pharmacy professionals to improve communications and collaborations with HTCs

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates these enduring materials for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation
Medical Education Resources designates these continuing education activities for 1.25 contact hour (0.125 CEU) of the Accreditation Council for Pharmacy Education.
UAN: 0816-9999-19-139-H01-P 1.25 contact hour.
This activity is certified as Knowledge-based CPE.

Nursing Continuing Education
Accreditation Statement 
Medical Education Resources, Inc. (MER) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. MER is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, the National Hemophilia Foundation and/or Takeda/Shire. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period September 30, 2019 through March 31, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.
For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.